Inozyme Pharma, Inc.

NasdaqGS:INZY Stok Raporu

Piyasa değeri: US$174.7m

Inozyme Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Inozyme Pharma CEO'su Doug Treco, Apr2023 tarihinde atandı, in görev süresi 1.58 yıldır. in toplam yıllık tazminatı $ 5.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.1% maaş ve 92.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.035% ine doğrudan sahiptir ve bu hisseler $ 60.86K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 6.6 yıldır.

Anahtar bilgiler

Doug Treco

İcra Kurulu Başkanı

US$5.3m

Toplam tazminat

CEO maaş yüzdesi7.1%
CEO görev süresi1.6yrs
CEO sahipliği0.03%
Yönetim ortalama görev süresi2.5yrs
Yönetim Kurulu ortalama görev süresi6.6yrs

Son yönetim güncellemeleri

Recent updates

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Nov 17
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Aug 03
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Jul 30

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Apr 11
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Mar 08

Inozyme Pharma GAAP EPS of -$0.38

Aug 15

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Jul 19

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Jul 12
Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Apr 06
We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Dec 22
Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Sep 08
Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

May 22
We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

May 07

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Feb 06
We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Jan 04

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Dec 03

Inozyme Pharma EPS misses by $1.02

Nov 12

CEO Tazminat Analizi

Doug Treco'un ücretlendirmesi Inozyme Pharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$96m

Jun 30 2024n/an/a

-US$89m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$375k

-US$71m

Sep 30 2023n/an/a

-US$68m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$106kn/a

-US$67m

Sep 30 2022n/an/a

-US$67m

Jun 30 2022n/an/a

-US$65m

Mar 31 2022n/an/a

-US$62m

Dec 31 2021US$188kn/a

-US$57m

Sep 30 2021n/an/a

-US$49m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$339kn/a

-US$56m

Tazminat ve Piyasa: Doug 'nin toplam tazminatı ($USD 5.30M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.44M ).

Tazminat ve Kazançlar: Doug şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Doug Treco (66 yo)

1.6yrs

Görev süresi

US$5,299,476

Tazminat

Dr. Douglas A. Treco, also known as Doug, Ph D., is an Advisor at LSV Capital Management LLC. Earlier he was a Scientific Advisor at the firm.He was Chief Executive Officer of Alchemab Therapeutics from A...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Douglas Treco
CEO & Chairman1.6yrsUS$5.30m0.035%
$ 60.9k
Axel Bolte
Co-Founderno dataUS$1.80m0.42%
$ 725.4k
Sanjay Subramanian
Senior VP2.7yrsUS$1.03m0.047%
$ 82.7k
Matthew Winton
Senior VP & COO1.6yrsUS$1.55m0.0076%
$ 13.3k
Demetrios Braddock
Co-Founderno dataVeri yokVeri yok
Soojin Kim
Senior VP & Chief Technical Operations Officer2.7yrsVeri yokVeri yok
David Thompson
Senior VP1.8yrsVeri yokVeri yok
Stefan Riley
Director of Investor Relationsno dataVeri yokVeri yok
Gayle Gironda
Senior VP & Chief People Officer3.3yrsVeri yokVeri yok
Yves Sabbagh
Chairman of Scientific Advisory Board & Senior VPno dataVeri yokVeri yok
Stephen J. Palma
Consultant2.7yrsVeri yokVeri yok
Kurt Gunter
Senior VP & Chief Medical Officer2.4yrsVeri yokVeri yok

2.5yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim: INZY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Douglas Treco
CEO & Chairman4.5yrsUS$5.30m0.035%
$ 60.9k
Axel Bolte
Co-Founder9.2yrsUS$1.80m0.42%
$ 725.4k
Demetrios Braddock
Co-Founderno dataVeri yokVeri yok
Yves Sabbagh
Chairman of Scientific Advisory Board & Senior VPno dataVeri yokVeri yok
Martin Edwards
Independent Director7.2yrsUS$129.65k0%
$ 0
Reinaldo Diaz
Lead independent director7.8yrsUS$130.27k0%
$ 0
Joseph Schlessinger
Member of Scientific Advisory Boardno dataUS$135.00kVeri yok
Edward Mathers
Independent Director7.8yrsUS$116.15k0%
$ 0
Robert Hopfner
Independent Director6yrsUS$112.15k0%
$ 0
Sarah Bhagat
Independent Director5.7yrsUS$114.65k0%
$ 0
Lynne Sullivan
Independent Director4.5yrsUS$122.15k0%
$ 0
Michael Levine
Chairperson of Clinical Advisory Boardno dataVeri yokVeri yok

6.6yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INZY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.6 yıldır).